Referenzen
Produkte Transfektion
Kostenlose Testsamples
Anwendungshinweise:
Im „Transfection Reagent Selection Guide“ können Sie durch Filterfunktionen z.B. für Ihre Kombination aus zu transfizierender Zelle und Nukleinsäure die Liste vorhandener Referenzen durchsuchen. Ebenso können Sie im Feld „Referenzen durchsuchen“ am Anfang der Seite mit passenden Schlagwörtern zu einem Ergebnis gelangen. Eine Referenz zeigt an, dass das gefundene Transfektionsreagenz bereits erfolgreich für die entsprechende Anwendung verwendet wurde. Im Idealfall sind getestete Transfektionsparameter und Transfektionseffizienzen angegeben.
Keine Referenz? > Allgemeine Auswahlhilfe
Wenn Sie keine Referenz gefunden haben, heißt das nicht, dass kein passendes Reagenz zur Verfügung steht, sondern lediglich, dass bisher keine Erfahrungsberichte vorliegen. In diesem Falle kann durch eine Vorauswahl ein erfolgsversprechendes Transfektionsreagenz ausgewählt (Allgemeine Auswahlhilfe) und letztendlich ausgetestet (Kostenlose Testsamples) werden. Wenn Sie einen Erfahrungsbericht für uns schreiben möchten machen wir Ihnen ein Angebot für eine Gegenleistung.
CELL TYPE | DESCRIPTION OF CELL TYPE | CAT.NO. | SPECIES | ORIGIN OF CELLS | COMMON CELL TYPE | GROWTH PROPERTIES | NUCLEIC ACID / DELIVERED MOLECULE | APPLICATION | PRODUCT | REFERENCE TYPE | BIBLIOGRAPHIC DATA | LINK | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | plasmid | stable transfection | Metafectene PRO | publication | R. Martınez-Marmol et al., Cell. Mol. Life Sci., 2016, 73:1515-1528; DOI 10.1007/s00018-015-2082-0 | |||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | K2 Transfection System | publication | E. Echeverria et al., Life Sciences, 2019, 239, 116872, doi.org/10.1016/j.lfs.2019.116872 | Link | ||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | cotransfection (plasmid/plasmid) | Metafectene EASY | publication | R. Hrdlickova et al., PLoS ONE, 2014, 9(2): e86990, doi:10.1371/journal.pone.0086990 | Link | |
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene EASY | publication | E. Roscioli et al., J. Cell Biol., Feb 2012; 196: 435 - 450 | Link | ||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | K2 Transfection System | publication | N. Liu, Albert-Ludwigs-Universität Freiburg | Link | ||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | M. G. Theis et al., PNAS, Aug 2004; 101: 11221 - 11226 | Link | ||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | cotransfection (plasmid/plasmid) | Metafectene | publication | K. Wethmar et al., Oncogene, 2016, 35,1736-1742; doi:10.1038/onc.2015.233 | Link | |
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene PRO | publication | K. Fortschegger et al., Mol. Cancer Res., Apr 2014; 12: 595 - 606 | Link | ||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | L. Vay et al., J. Physiol., 2007, 580.1, 39-49 | |||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | L. Silvestri et al., Hum. Mol. Genet., Nov 2005; 14: 3477 - 3492 | Link | ||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | cotransfection (plasmid/plasmid) | Metafectene | publication | A. Raturi et al., J. Cell Biol., Aug 2016; 214, 433 - 444 | ||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | stable transfection | Metafectene PRO | publication | Y. P. Abudu et al., J. Cell Biol., 2021, 220(8): e202009092, doi: 10.1083/jcb.202009092 | Link | |
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | T.-H. Kang et al., Mol. Cell. Biol., Dec 2007; 27: 8533 - 8546 | Link | ||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene PRO | publication | S. Gebremedhin et al., Biophysical J., 2014, 106(2): 625a | Link | ||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | stable transfection | Metafectene | publication | C. T. Hellwig et al., J. Biol. Chem., Aug 2008; 283: 21676 - 21685 | Link | |
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | stable transfection | Metafectene EASY | publication | M. De Luca et al., J. Cell Sci., Jun 2014; 127: 2697 - 2708 | Link | |
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene PRO | publication | R. Romano et al., Cell. and Mol. Life Sci., 2021, 78: 351–372, 78:351–372, doi.org/10.1007/s00018-020-03510-1 | Link | ||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | S. Cohen et al., Biochim. et Biophysica Acta, 2013, 1833: 1104–1113, doi.org/10.1016/j.bbamcr.2012.12.021 | Link | ||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | D.W. Chen et al., In: C. Boon, J. Wijnholds (eds) Retinal Gene Therapy. Methods in Molecular Biology, 2018, 1715, Humana Press, NY | |||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | Z. Knust et al., Infect. Immun., May 2009; 77: 1835 - 1841 | Link | ||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | M. M. Nalaskowski et al., J. Biol. Chem., Feb 2011; 286: 4500 - 4510 | Link | ||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | stable transfection | Metafectene | publication | S. de la Fuente et al., Biochem. J., 2014, 458: 33-40, doi:10.1042/BJ20131025 | ||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | L. Rampoldi et al., Hum. Mol. Genet., Dec 2003; 12: 3369 - 3384 | Link | ||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | cotransfection (plasmid/plasmid) | Metafectene | publication | J. Schulz et al., Scientific Reports, 2018, 8: 2395, DOI:10.1038/s41598-018-19201-8 | Link | |
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | E. M. Lynes et al., J. Cell Sci., Sep 2013; 126: 3893 - 3903 | Link |